Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Mar 23;23(1):265.
doi: 10.1186/s12885-023-10708-6.

Impact of COVID-19 in patients on active melanoma therapy and with history of melanoma

Collaborators, Affiliations

Impact of COVID-19 in patients on active melanoma therapy and with history of melanoma

Douglas B Johnson et al. BMC Cancer. .

Abstract

Introduction: COVID-19 particularly impacted patients with co-morbid conditions, including cancer. Patients with melanoma have not been specifically studied in large numbers. Here, we sought to identify factors that associated with COVID-19 severity among patients with melanoma, particularly assessing outcomes of patients on active targeted or immune therapy.

Methods: Using the COVID-19 and Cancer Consortium (CCC19) registry, we identified 307 patients with melanoma diagnosed with COVID-19. We used multivariable models to assess demographic, cancer-related, and treatment-related factors associated with COVID-19 severity on a 6-level ordinal severity scale. We assessed whether treatment was associated with increased cardiac or pulmonary dysfunction among hospitalized patients and assessed mortality among patients with a history of melanoma compared with other cancer survivors.

Results: Of 307 patients, 52 received immunotherapy (17%), and 32 targeted therapy (10%) in the previous 3 months. Using multivariable analyses, these treatments were not associated with COVID-19 severity (immunotherapy OR 0.51, 95% CI 0.19 - 1.39; targeted therapy OR 1.89, 95% CI 0.64 - 5.55). Among hospitalized patients, no signals of increased cardiac or pulmonary organ dysfunction, as measured by troponin, brain natriuretic peptide, and oxygenation were noted. Patients with a history of melanoma had similar 90-day mortality compared with other cancer survivors (OR 1.21, 95% CI 0.62 - 2.35).

Conclusions: Melanoma therapies did not appear to be associated with increased severity of COVID-19 or worsening organ dysfunction. Patients with history of melanoma had similar 90-day survival following COVID-19 compared with other cancer survivors.

Keywords: COVID-19; Cancer; Immune therapy; Melanoma; Targeted therapy.

PubMed Disclaimer

Conflict of interest statement

DBJ has served on advisory boards or as a consultant for BMS, Catalyst Biopharma, Iovance, Jansen, Mallinckrodt, Merck, Mosaic ImmunoEngineering, Novartis, Oncosec, Pfizer, Targovax, and Teiko, and has received research funding from BMS and Incyte. CRF has received institutional research support from the Merck Foundation and the National Comprehensive Cancer Network (via Pfizer). DF has received research support from Astellas, Viracor, and Merck, and consultant fee from Viracor. LAF has received clinical trial funding from BMS, Kartos, Array-Pfizer, EMD Serono, and as a consultant for Elsevier. GHL reports research grant support from Amgen to the Fred Hutchinson Cancer Center and consulting fees from Beyond Spring, G1 Therapeutics, Partner Therapeutics, Squibb, Samsung Bioepis, Merck, Jazz, TEVA, Seattle Genetics and Frensenius Kabi. Other authors declare no conflicts of interest relevant to the work.

Figures

Fig. 1
Fig. 1
Distribution of the ordinal COVID-19 severity outcome, stratified by modality of anti-cancer therapy received within 3 months prior to COVID-19 diagnosis. Note: The ordinal COVID-19 severity outcome was based on a patient’s most severe reported disease status during follow-up (for example, a patient who was hospitalized and later died is included in “Died”). The width of the boxes is proportional to the number of patients who received each anti-cancer therapy; the height of the boxes is proportional to the number of patients in each outcome level. Patient numbers are listed for each outcome level

References

    1. Elkrief A, Wu JT, Jani C, et al. Learning through a Pandemic: The Current State of Knowledge on COVID-19 and Cancer. Cancer Discov. 2022;12(2):303–330. doi: 10.1158/2159-8290.CD-21-1368. - DOI - PMC - PubMed
    1. Kuderer NM, Choueiri TK, Shah DP, et al. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. Lancet. 2020;395(10241):1907–1918. doi: 10.1016/S0140-6736(20)31187-9. - DOI - PMC - PubMed
    1. Grivas P, Khaki AR, Wise-Draper TM, et al. Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium. Ann Oncol. 2021;32(6):787–800. doi: 10.1016/j.annonc.2021.02.024. - DOI - PMC - PubMed
    1. Covid, Cancer Consortium Electronic address jwvo, Covid, Cancer C. A Systematic Framework to Rapidly Obtain Data on Patients with Cancer and COVID-19: CCC19 Governance, Protocol, and Quality Assurance. Cancer cell. 2020;38(6):761–766. doi: 10.1016/j.ccell.2020.10.022. - DOI - PMC - PubMed
    1. French B, Shotwell MS. Regression Models for Ordinal Outcomes. JAMA. 2022;328(8):772–773. doi: 10.1001/jama.2022.12104. - DOI - PubMed